美股异动丨雅培跌超12%创2024年7月以来新低，Q4营收逊于预期

Core Viewpoint - Abbott Laboratories (ABT.US) shares fell over 12%, reaching a low of $105.79, marking the lowest point since July 2024, primarily due to disappointing Q4 revenue results [1] Group 1: Financial Performance - Abbott's Q4 revenue was $11.46 billion, falling short of analysts' average expectations of $11.8 billion [1] - The decline in revenue was largely attributed to a sharp decrease in demand for COVID-19 testing within the diagnostics segment, compounded by the impact of the Trump administration's freeze on foreign aid [1] - Adjusted earnings per share were reported at $1.50, reflecting a 12% year-over-year increase [1] Group 2: Business Outlook - The CEO of Abbott indicated that the nutrition segment is expected to face challenges in the first half of 2026, with a forecasted recovery in growth anticipated in the latter half of the year [1]